HTG MOLECULAR DIAGNOSTICS (HTGM) Fundamental Analysis & Valuation
NASDAQ:HTGM • US40434H3021
Current stock price
0.48 USD
-0.12 (-20%)
At close:
0.4815 USD
+0 (+0.31%)
After Hours:
This HTGM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. HTGM Profitability Analysis
1.1 Basic Checks
- In the past year HTGM has reported negative net income.
- In the past year HTGM has reported a negative cash flow from operations.
1.2 Ratios
- HTGM has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HTGM has a Gross Margin of 21.69%. This is in the lower half of the industry: HTGM underperforms 79.55% of its industry peers.
- HTGM's Gross Margin has declined in the last couple of years.
- HTGM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
2. HTGM Health Analysis
2.1 Basic Checks
- HTGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, HTGM has more shares outstanding
- HTGM has a better debt/assets ratio than last year.
2.2 Solvency
- HTGM has an Altman-Z score of -35.30. This is a bad value and indicates that HTGM is not financially healthy and even has some risk of bankruptcy.
- HTGM has a Altman-Z score of -35.30. This is amonst the worse of the industry: HTGM underperforms 90.91% of its industry peers.
- HTGM has a Debt/Equity ratio of 7.10. This is a high value indicating a heavy dependency on external financing.
- HTGM has a worse Debt to Equity ratio (7.10) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.1 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -35.3 |
ROIC/WACCN/A
WACC4.37%
2.3 Liquidity
- A Current Ratio of 1.40 indicates that HTGM should not have too much problems paying its short term obligations.
- HTGM's Current ratio of 1.40 is on the low side compared to the rest of the industry. HTGM is outperformed by 61.36% of its industry peers.
- HTGM has a Quick Ratio of 1.30. This is a normal value and indicates that HTGM is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of HTGM (1.30) is worse than 61.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.3 |
3. HTGM Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 44.99% over the past year.
- The Revenue for HTGM has decreased by -28.21% in the past year. This is quite bad
- The Revenue for HTGM have been decreasing by -15.48% on average. This is quite bad
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.54%
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Sales Q2Q%-12.83%
3.2 Future
- HTGM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.92% yearly.
- HTGM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.55% yearly.
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. HTGM Valuation Analysis
4.1 Price/Earnings Ratio
- HTGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year HTGM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as HTGM's earnings are expected to grow with 39.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.92%
EPS Next 3YN/A
5. HTGM Dividend Analysis
5.1 Amount
- HTGM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HTGM Fundamentals: All Metrics, Ratios and Statistics
0.48
-0.12 (-20%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10 2023-05-10/amc
Earnings (Next)08-09 2023-08-09/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners201.96%
Ins Owner Change0%
Market Cap1.06M
Revenue(TTM)6.21M
Net Income(TTM)-20.15M
Analysts82.86
Price Target6.12 (1175%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-48.59%
Min EPS beat(2)-81.95%
Max EPS beat(2)-15.22%
EPS beat(4)2
Avg EPS beat(4)-14.95%
Min EPS beat(4)-81.95%
Max EPS beat(4)24.87%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.27%
Min Revenue beat(2)-36.73%
Max Revenue beat(2)-1.8%
Revenue beat(4)0
Avg Revenue beat(4)-34.25%
Min Revenue beat(4)-56.97%
Max Revenue beat(4)-1.8%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-40%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-162.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-67.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.24 | ||
| P/tB | 2.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-18.15
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-7.61
FCFYN/A
OCF(TTM)-7.6
OCFYN/A
SpS2.81
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.69% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.29%
GM growth 5Y-15.73%
F-Score3
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 7.1 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.28% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.4 | ||
| Quick Ratio | 1.3 | ||
| Altman-Z | -35.3 |
F-Score3
WACC4.37%
ROIC/WACCN/A
Cap/Depr(3y)42.2%
Cap/Depr(5y)55.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.54%
EPS Next Y81.55%
EPS Next 2Y39.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-28.21%
Revenue growth 3Y-30.79%
Revenue growth 5Y-15.48%
Sales Q2Q%-12.83%
Revenue Next Year0.6%
Revenue Next 2Y53.55%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.73%
OCF growth 3YN/A
OCF growth 5YN/A
HTG MOLECULAR DIAGNOSTICS / HTGM Fundamental Analysis FAQ
What is the ChartMill fundamental rating of HTG MOLECULAR DIAGNOSTICS (HTGM) stock?
ChartMill assigns a fundamental rating of 2 / 10 to HTGM.
What is the valuation status for HTGM stock?
ChartMill assigns a valuation rating of 1 / 10 to HTG MOLECULAR DIAGNOSTICS (HTGM). This can be considered as Overvalued.
Can you provide the profitability details for HTG MOLECULAR DIAGNOSTICS?
HTG MOLECULAR DIAGNOSTICS (HTGM) has a profitability rating of 1 / 10.
Can you provide the financial health for HTGM stock?
The financial health rating of HTG MOLECULAR DIAGNOSTICS (HTGM) is 1 / 10.
What is the expected EPS growth for HTG MOLECULAR DIAGNOSTICS (HTGM) stock?
The Earnings per Share (EPS) of HTG MOLECULAR DIAGNOSTICS (HTGM) is expected to grow by 81.55% in the next year.